Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ritobegron Specificity and Interaction Study in Healthy Males
NCT02256722Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2005
- Primary completion
- Nov 2005
01
Overview
Phase 1, randomised, open-label trial of ritobegron in overactive bladder (OAB) (5 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Absolute change from baseline in glucose at 24 hours, Percentage change from baseline in glucose at 24 hours and 12 more. Started Oct 2005; status: completed.
02
Drugs
ritobegron
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT02256722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02256722.